Literature DB >> 3397267

Anti AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis.

R Mantegazza1, D Pareyson, F Baggi, P Romagnoli, D Peluchetti, A Sghirlanzoni, F Cornelio.   

Abstract

227 sera from myasthenic patients were tested for the presence of anti-AChR antibodies (anti-AChR Abs) by mean of a fetal calf receptor (Fc-AChR); 73.5% of cases proved positive with this method. Significant correlations were found between presence of anti-Fc-AChr Abs and various clinical aspects such as: clinical stage and duration of disease; moreover significantly higher than the median titers were found among younger patients (i.e. age less than 40 yrs).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3397267     DOI: 10.1007/bf02337460

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  22 in total

1.  A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.

Authors:  V M Monnier; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

2.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.

Authors:  A G Engel; E H Lambert; F M Howard
Journal:  Mayo Clin Proc       Date:  1977-05       Impact factor: 7.616

3.  Myasthenia gravis: prolonged treatment with steroids.

Authors:  A Sghirlanzoni; D Peluchetti; R Mantegazza; F Fiacchino; F Cornelio
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

4.  Immune disease and HLA associations with myasthenia gravis.

Authors:  P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

5.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

Review 6.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

7.  Differences in the interaction of acetylcholine receptor antibodies with receptor from normal, denervated and myasthenic human muscle.

Authors:  A K Lefvert
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-01       Impact factor: 10.154

8.  New antigen for antibody detection in myasthenia gravis.

Authors:  C Gotti; R Mantegazza; F Clementi
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

9.  [Assay of acetylcholine receptor antibodies in myasthenia gravis. A study of 329 sera (author's transl)].

Authors:  E Morel; F Raimond; C Goulon-Goëau; S Berrih; B Vernet-Der-Garabedian; J Harb; J F Bach
Journal:  Nouv Presse Med       Date:  1982-05-22

10.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

View more
  5 in total

1.  Clinical implementation of anti-acetylcholine receptor antibodies.

Authors:  F E Somnier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

2.  Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Authors:  Srikanth Muppidi; Kimiaki Utsugisawa; Michael Benatar; Hiroyuki Murai; Richard J Barohn; Isabel Illa; Saiju Jacob; John Vissing; Ted M Burns; John T Kissel; Richard J Nowak; Henning Andersen; Carlos Casasnovas; Jan L de Bleecker; Tuan H Vu; Renato Mantegazza; Fanny L O'Brien; Jing Jing Wang; Kenji P Fujita; James F Howard
Journal:  Muscle Nerve       Date:  2019-03-08       Impact factor: 3.217

3.  Consistent improvement with eculizumab across muscle groups in myasthenia gravis.

Authors:  Renato Mantegazza; Fanny L O'Brien; Marcus Yountz; James F Howard
Journal:  Ann Clin Transl Neurol       Date:  2020-07-22       Impact factor: 4.511

4.  Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.

Authors:  Richard J Nowak; Srikanth Muppidi; Said R Beydoun; Fanny L O'Brien; Marcus Yountz; James F Howard
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

5.  'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.

Authors:  John Vissing; Saiju Jacob; Kenji P Fujita; Fanny O'Brien; James F Howard
Journal:  J Neurol       Date:  2020-03-18       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.